Pegram MD - Search Results

1

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. Among authors: pegram md. JAMA Oncol. 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932. JAMA Oncol. 2021. PMID: 33480963 Free PMC article. Clinical Trial.

2

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

Pegram MD, Slamon DJ. Pegram MD, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):89-95. Semin Oncol. 1999. PMID: 10482199 Clinical Trial.

3

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.

Pegram M, Slamon D. Pegram M, et al. Semin Oncol. 2000 Oct;27(5 Suppl 9):13-9. Semin Oncol. 2000. PMID: 11049052

4

Trastuzumab and chemotherapeutics: drug interactions and synergies.

Pegram MD, Lopez A, Konecny G, Slamon DJ. Pegram MD, et al. Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100. Semin Oncol. 2000. PMID: 11236023

5

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

Slamon D, Pegram M. Slamon D, et al. Semin Oncol. 2001 Feb;28(1 Suppl 3):13-9. doi: 10.1016/s0093-7754(01)90188-5. Semin Oncol. 2001. PMID: 11301370 Review.

6

Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.

Pegram MD, O'Callaghan C. Pegram MD, et al. Clin Breast Cancer. 2001 Oct;2 Suppl 1:S15-9. doi: 10.3816/cbc.2001.s.003. Clin Breast Cancer. 2001. PMID: 11970740 Review.

7

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.

Pegram MD, Reese DM. Pegram MD, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37. doi: 10.1053/sonc.2002.34053. Semin Oncol. 2002. PMID: 12138395 Review.

8

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Pegram MD, et al. J Natl Cancer Inst. 2004 May 19;96(10):739-49. doi: 10.1093/jnci/djh131. J Natl Cancer Inst. 2004. PMID: 15150302

9

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. Pegram MD, et al. J Natl Cancer Inst. 2004 May 19;96(10):759-69. doi: 10.1093/jnci/djh133. J Natl Cancer Inst. 2004. PMID: 15150304 Clinical Trial.

10

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ. Hurley J, et al. Among authors: pegram md. J Clin Oncol. 2006 Apr 20;24(12):1831-8. doi: 10.1200/JCO.2005.02.8886. Epub 2006 Mar 20. J Clin Oncol. 2006. PMID: 16549824 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters